Publications
NET RETREAT the CCTG NE1 trial has recently opened in North America looking to compare retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment in patients with metastatic midgut neuroendocrine tumours.
Neoadjuvant Chemotherapy, Excision And Observation Vs Chemoradiotherapy For Early Rectal Cancer. The NEO-RT Trial
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma
Ibrutinib Combination Therapy in Transplant Ineligible Individuals with Newly Diagnosed Primary CNS Lymphoma
OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
Tusamitamab Ravtansine (Tusa) Vs Investigator Choice in CEACAM5+ NSCLC After the Failure of Standard of Care Systemic Therapy
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
The purpose of this study is to see the effects on you and your lymphoma of a new drug combination compared to other drugs that are currently used in standard treatment.
One of the treatments for multiple myeloma is with three medicines, all continued indefinitely until they stop working, or side effects happen. Two are tablets, and the third is an injection. In this study, we are testing if the injection can be stopped after around 18 months of treatment with no change to how your multiple myeloma is being controlled.
The purpose of this study is to compare the usual treatment for your Hodgkin lymphoma, which is a standard combination of four drugs, versus the standard combination with one drug of the combination replaced with a new drug that we hope will be more effective and cause you fewer side effects.
The purpose of this trial is to find out if people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) will live longer and have a better quality of life if they start treatment earlier. Some people do not have major symptoms when they are diagnosed with CLL or SLL. Treatment is often started when they show symptoms such as fever, anemia, or night sweats. Studies have shown that early treatment using older chemotherapy drugs doesn’t improve outcomes compared to later treatment.